Recent Updates
Recently added Catalysts
CORT Positive Sentiment

TRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Saturday, May 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The TRIDENT study investigates the efficacy of relacorilant combined with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic ductal adenocarcinoma. Presented at the American Society of Clinical Oncology Annual Meeting, the study aims to provide insights into new treatment options for this challenging cancer type.
Price reaction · baseline $69.49 (2026-05-29 close) · 1 other CORT headline(s) in the window, move may be shared
day 0 close · peak
+1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study focuses on a novel combination therapy for pancreatic cancer.
  • Relacorilant shows potential in treating chemotherapy-naïve patients.
  • The presentation at a major conference highlights its significance.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+283%
120-day peak, hindsight
Typical move
12.9%
average across 6 past catalysts
Lead asset
CORT118335
Phase 1 · Antipsychotic-induced Weight Gain

Full Press Release Details

Presented : American Society of Clinical Oncology Annual Meeting , 30 May 2026, Chicago, IL
Presenter : Erkut H. Borazanci , MD, MS
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Poster
The post TRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal Adenocarcinoma appeared first on Corcept Therapeutics .

Frequently Asked Questions

What is the TRIDENT study about?

The TRIDENT study examines relacorilant combined with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic ductal adenocarcinoma.

Where was the TRIDENT study presented?

The study was presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

Who presented the TRIDENT study?

Dr. Erkut H. Borazanci, MD, MS, presented the TRIDENT study.

What type of patients were involved in the TRIDENT study?

The study involved chemotherapy-naïve patients with metastatic pancreatic ductal adenocarcinoma.

ShareAdd on Google
Tags: CORT relacorilant pancreatic cancer chemotherapy ASCO 2026
Last updated: May 30, 2026

Biotech snapshot

Cash runway
$545M liquidity · $0M/mo burn
Low dilution risk
Lead asset
CORT118335Phase 1
Antipsychotic-induced Weight Gain →

Catalyst track record

+283%
best trade around CORT's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CORT.

See every catalyst's timing & PoA →